Hunting for Mutations in Indian Patients with Hunter Syndrome

KATTA M GIRISHA
Department of Medical Genetics, Kasturba Medical College, Manipal, Manipal University, Karnataka, India.
girish.katta@manipal.edu

Hunter syndrome, also known as mucopolysaccharidosis type II, is an X-linked lysosomal storage disease predominantly affecting the central nervous system, bones, heart and lungs in a progressive manner. Affected individuals also have coarse facial features and joint contractures, but the severity of all manifestations is highly variable. Supportive care was the only therapeutic option until recently when enzyme replacement therapy became available. Hematopoietic stem cell transplantation is another treatment option for these patients. As is true for most genetic diseases, the exact incidence and prevalence rates for this condition in India is not known, though it is expected that India has one of the largest burden of genetic disorders [1]. Enzyme replacement therapy is very expensive at present and is beyond the reach of most. Prenatal diagnosis is an option considered by many Indian families for this condition.

As a practicing clinical geneticist and researcher, I often find that mutation data are scarce for Indian patients, even for common genetic conditions. Databases for normal sequence variations also highly under-represent the Indian scenario. This under-representation puts clinicians and researchers in a very tough situation to decipher the pathogenicity of DNA sequence variations that they encounter during diagnostic testing and research. Most often, we end up extrapolating data from rest of the world and apply it to our population, which is not ideal.

Identifying mutations in a genetic disease not only helps us confirm the diagnosis, but it also enables definitive prenatal diagnosis for the families. In this issue of Indian Pediatrics, Narayanan, et al. [2] present the clinical profile and mutation spectrum of Indian patients with Hunter syndrome. Though the number of study children is very small, this is probably the way to begin addressing these rare genetic disorders in our country. Several earlier publications have suggested that Indians might have unique or private mutations for monogenic disorders [3-5]. Further, India being the second most populous country in the world, provides a great opportunity for creation of disease-specific mutation databases. In fact, we now have some publications describing the largest series of patients with mutations in the genes studied [3,6-9]. Genetic studies on lysosomal storage diseases are now facilitated by the National Task Force on Lysosomal Storage Diseases established by the Indian Council of Medical Research, New Delhi. I hope these efforts culminate in much needed mutation data for Indians with these genetic conditions thus facilitating their diagnosis, management and prevention.

Funding: None; Competing interest: The author is a member of National Task Force on Lysosomal Storage Disease, funded by ICMR and Department of Health Research.

REFERENCES